Sickle Cell Disease Clinical Trials in Nashville, Tennessee

5 studies are recruiting for sickle cell disease in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

   In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

   Stage

   Not phased

   Ages

   Any age

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   76 in total

   Run by

   American Thrombosis and Hemostasis Network

   See if you can join NCT04398628 on ClinicalTrials.gov

2. Cooperative Assessment of Late Effects for SCD Curative Therapies

   Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >…

   Stage

   Not phased

   Ages

   4 to 65

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   5 in total

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT05153967 on ClinicalTrials.gov

3. Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

   This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

   Stage

   Phase 3

   Ages

   12 to 35

   Site

   TriStar Medical Group Children's Specialists - Pediatric Oncology, Nashville, Tennessee

   Locations

   6 in total

   Run by

   Vertex Pharmaceuticals Incorporated

   See if you can join NCT05477563 on ClinicalTrials.gov

4. Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease

   In a hybrid type I effectiveness-implementation trial, our three-center research teams aim to examine whether empowering adults with sickle cell disease (SCD) with patient-facing SCD-specific guidelines through an mHealth application with booklets will decrease acute healthcare utilization and be c…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University, Nashville, Tennessee

   Locations

   4 in total

   Run by

   Ohio State University

   See if you can join NCT06919224 on ClinicalTrials.gov

5. A Long-term Follow-up Study in Patients Who Received BEAM-101

   This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed fo…

   Stage

   Not phased

   Ages

   14 to 37

   Site

   The Children's Hospital at TriStar Centennial, Nashville, Tennessee

   Locations

   17 in total

   Run by

   Beam Therapeutics Inc.

   See if you can join NCT07373639 on ClinicalTrials.gov